Journal
RADIOTHERAPY AND ONCOLOGY
Volume 96, Issue 2, Pages 145-152Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.radonc.2010.07.001
Keywords
Heterogeneity; Non-small cell lung cancer (NSCLC); Fluorodeoxyglucose (FDG); Dose-painting; Dose redistribution; Biological dose optimization
Funding
- CTMM, the Center for Translational Molecular Medicine [030-103]
- European Union [222741]
Ask authors/readers for more resources
Evidence is accumulating that radiotherapy of non-small cell lung cancer patients can be optimized by escalating the tumour dose until the normal tissue tolerances are met To further improve the therapeutic ratio between tumour control probability and the risk of normal tissue complications, we firstly need to exploit Inter patient variation This variation arises, e g. from differences in tumour shape and size, lung function and genetic factors Secondly improvement is achieved by taking into account intra-tumour and intra-organ heterogeneity derived from molecular and functional imaging Additional radiation dose must be delivered to those parts of the tumour that need It the most, e g because of increased radio-resistance or reduced therapeutic drug uptake, and away from regions inside the lung that are most prone to complication As the delivery of these treatments plans is very sensitive for geometrical uncertainties, probabilistic treatment planning is needed to generate robust treatment plans The administration of these complicated dose distributions requires a quality assurance procedure that can evaluate the treatment delivery and, if necessary, adapt the treatment plan during radiotherapy (C) 2010 Elsevier Ireland Ltd All rights reserved Radiotherapy and Oncology 96 (2010) 145-152
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available